Live attenuated Salmonella enterica serovar Choleraesuis vector delivering a virus-like particles induces a protective immune response against porcine circovirus type 2 in mice. Issue 33 (5th August 2022)

• Record Type: Journal Article
• Authors: Li, Yu-an; Sun, Yanni; Zhang, Yuqin; Wang, Shifeng; Shi, Huoying
• Is Part Of: Vaccine. Volume 40:Issue 33(2022)
• Page Start: 4732
• Page End: 4741
• Publication Date: 2022-08-05
• Subjects: Virus-like particles -- Attenuated S. Choleraesuis vector -- Cap protein -- PCV2 vaccine; PCV2 Porcine circovirus type 2 -- Cap Capsid -- DMEM Dulbecco's Modified Eagle Medium -- PVDF Polyvinylidene fluoride -- PTA Phosphotungstic acid -- IFAs Indirect Immunofluorescence Assays -- LB Luria broth -- TCID50 50% tissue culture infective dose -- Th1 T helper type 1 -- Th2 T helper type 2 -- PBS Phosphate buffer saline -- SDS Sodium dodecyl sulphate-polyacrylamide -- ADCC Ab-dependent cell-mediated cytotoxicity -- NK cells natural killer cells; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.06.046
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: An inexpensive and efficient virus-like particles production platform based on Salmonella Choleraesuis vector. PCV2 oral vaccine induces mucosal immune response and Th1-dominant response. A Prokaryotic expression system for the production of virus-like particles based on Salmonella Choleraesuis vector. Abstract: The virus-like particles (VLPs) of porcine circovirus type 2 (PCV2) is an attractive vaccine candidate that retains the natural conformation of the virion but lacks the viral genome to replicate, thus balancing safety and immunogenicity. However, the assembly of VLPs requires cumbersome subsequent processes, hindering the development of related vaccines. In addition, as a subunit antigen, VLPs are defective in inducing cellular and mucosal immune responses. In this study, the capsid (Cap) protein of PCV2 was synthesized and self-assembled into VLPs in the recombinant attenuated S . Choleraesuis vector, rSC0016(pS-Cap). Furthermore, rSC0016(pS-Cap) induced a Cap-specific Th1-dominant immune response, mucosal immune responses, and neutralizing antibodies against PCV2. Finally, the virus genome copies in mice immunized with the rSC0016(pS-Cap) were significantly lower than those of the empty vector control group after challenge with PCV2. In conclusion, our study demonstrates the potential of using S . Choleraesuis vectors to delivery VLPs, providing new ideas for the development of PCV2 vaccines.